{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:35:52Z","timestamp":1794274552368,"version":"4.9.0"},"reference-count":224,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Myasthenia gravis (MG) is the most extensively studied antibody-mediated disease in humans. Substantial progress has been made in the treatment of MG in the last century, resulting in a change of its natural course from a disease with poor prognosis with a high mortality rate in the early 20th century to a treatable condition with a large proportion of patients attaining very good disease control. This review summarizes the current treatment options for MG, including non-immunosuppressive and immunosuppressive treatments, as well as thymectomy and targeted immunomodulatory drugs.<\/jats:p>","DOI":"10.3390\/jcm11061597","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T03:34:13Z","timestamp":1647401653000},"page":"1597","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Current Treatment of Myasthenia Gravis"],"prefix":"10.3390","volume":"11","author":[{"given":"Mohammed K.","family":"Alhaidar","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Chicago Medical Center, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumayyah","family":"Abumurad","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago Medical Center, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Soliven","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago Medical Center, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3986-5709","authenticated-orcid":false,"given":"Kourosh","family":"Rezania","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago Medical Center, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dresser, L., Wlodarski, R., Rezania, K., and Soliven, B. (2021). Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112235"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/brain\/23.2.277","article-title":"Myasthenia gravis pseudoparalytica: Review of 70 case reports, including nine new patients","volume":"23","author":"Campbell","year":"1900","journal-title":"Brain"},{"key":"ref_3","first-page":"216","article-title":"Myasthenia Gravis: A Clinical Review of Eighty-Seven Cases Observed between 1915 and the Early Part of 1932","volume":"37","author":"Kennedy","year":"1937","journal-title":"Can. Med. Assoc. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jama.1953.02940230001001","article-title":"Course and management of myasthenia gravis","volume":"153","author":"Grob","year":"1953","journal-title":"J. Am. Med. Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00000658-193910000-00005","article-title":"Myasthenia Gravis and Tumors of the Thymic Region: Report of a Case in Which the Tumor Was Removed","volume":"110","author":"Blalock","year":"1939","journal-title":"Ann. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1172\/JCI101336","article-title":"Observations on the Nature of Myasthenia Gravis. The Effect of Thymectomy on Neuro-Muscular Transmission","volume":"21","author":"Harvey","year":"1942","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized Trial of Thymectomy in Myasthenia Gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.1966.03110200059018","article-title":"Corticotropin in generalized myasthenia gravis. Effect of short, intensive courses","volume":"198","author":"Grob","year":"1966","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1749-6632.1971.tb30743.x","article-title":"Myasthenia gravis: A new hypothesis of the pathogenesis and a new form of treatment","volume":"183","author":"Engel","year":"1971","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000113809","article-title":"The Treatment of Severe Myasthenia Gravis with Immunosuppressive Agents","volume":"2","author":"Mertens","year":"1969","journal-title":"Eur. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJM197711242972102","article-title":"Plasmapheresis and Immunosuppressive Drug Therapy in Myasthenia Gravis","volume":"297","author":"Dau","year":"1977","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(84)90469-0","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis","volume":"323","author":"Gajdos","year":"1984","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(84)92294-3","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis","volume":"323","author":"Wick","year":"1984","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0140-6736(84)90729-3","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis","volume":"324","author":"Ippoliti","year":"1984","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(79)90823-7","article-title":"Long-term effects of repeated plasma exchange in myasthenia gravis","volume":"313","author":"Wilson","year":"1979","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0140-6736(76)91917-6","article-title":"Remission of myasthenia gravis following plasma-exchange","volume":"2","author":"Pinching","year":"1976","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1196\/annals.1405.033","article-title":"Rebooting the Immune System with High-Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis","volume":"1132","author":"Drachman","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaneurol.2016.0113","article-title":"Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation","volume":"73","author":"Bryant","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.etap.2004.12.048","article-title":"Pharmacology and toxicology of cholinesterase inhibitors: Uses and misuses of a common mechanism of action","volume":"19","author":"Pope","year":"2005","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0140-6736(00)94294-6","article-title":"Treatment of myasthenia gravis with physostigmine","volume":"223","author":"Walker","year":"1934","journal-title":"Lancet"},{"key":"ref_22","first-page":"759","article-title":"Case showing the Effect of Prostigmin on Myasthenia Gravis","volume":"28","author":"Walker","year":"1935","journal-title":"Proc. R. Soc. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/bmj.1.3870.463","article-title":"Clinical Observations on the Use of Prostigmin in the Treatment of Myasthenia Gravis","volume":"1","author":"Laurent","year":"1935","journal-title":"Br. Med. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ncl.2018.01.003","article-title":"Ocular myasthenia","volume":"36","author":"Benatar","year":"2018","journal-title":"Neurol. Clin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archopht.1959.04220060057010","article-title":"Evaluation of Ocular Signs and Symptoms in Myasthenia Gravis","volume":"62","author":"Schlezinger","year":"1959","journal-title":"Arch. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9343(55)80018-6","article-title":"Progress report on mestinon bromide (pyridostigmine bromide)","volume":"19","author":"Osserman","year":"1955","journal-title":"Am. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jama.1954.03690290011004","article-title":"Studies in myasthenia gravis; preliminary report on therapy with mestinon bromide","volume":"155","author":"Osserman","year":"1954","journal-title":"J. Am. Med. Assoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0002-9343(55)80006-X","article-title":"Pharmacology of the anticholinesterase drugs; mestinon, prostigmin, tensilon and TEPP","volume":"19","author":"Randall","year":"1955","journal-title":"Am. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/WNL.4.10.762","article-title":"Mestinon in the Treatment of Myasthenia Gravis","volume":"4","author":"Westerberg","year":"1954","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/archinte.1958.00260190074008","article-title":"Studies in myasthenia gravis; review of two hundred eighty-two cases at the Mount Sinai Hospital, New York City","volume":"102","author":"Osserman","year":"1958","journal-title":"AMA Arch. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.1956.02960380004002","article-title":"Treatment of myasthenia gravis with mestinon bromide","volume":"160","author":"Tether","year":"1956","journal-title":"J. Am. Med. Assoc."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Prinscott, J. (1988). The Patient with Myasthenia Gravis. Preanesthetic Assessment 1, Birkh\u00e4user.","DOI":"10.1007\/978-1-4612-4818-7_13"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/00003246-199806000-00044","article-title":"Therapy of Myasthenic Crisis","volume":"26","author":"Mayer","year":"1998","journal-title":"Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12028-021-01259-4","article-title":"Acetylcholinesterase Inhibitors in Myasthenic Crisis: A Systematic Review of Observational Studies","volume":"35","author":"Prado","year":"2021","journal-title":"Neurocritical Care"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sheikh, S., Alvi, U., Soliven, B., and Rezania, K. (2021). Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071537"},{"key":"ref_37","first-page":"7","article-title":"Myasthenia Gravis: Its Treatment by a Combination of Prostigmin and Glycine-Ephedrine Therapy","volume":"128","author":"Macfarlane","year":"1937","journal-title":"Glasg. Med. J."},{"key":"ref_38","first-page":"CD010028","article-title":"Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes","volume":"2014","author":"Vrinten","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0889-1591(90)90003-9","article-title":"Sympathetic nervous system and PC12 pheochromocytoma-derived factors suppress stimulation of lymphocytes","volume":"4","author":"Checinski","year":"1990","journal-title":"Brain Behav. Immun."},{"key":"ref_40","first-page":"487","article-title":"Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo","volume":"53","author":"Kohm","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0192-0561(93)90027-V","article-title":"The beta 2-adrenergic agonist terbutaline suppresses acute passive transfer experimental autoimmune myasthenia gravis (EAMG)","volume":"15","author":"Wollmann","year":"1993","journal-title":"Int. J. Immunopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jns.2008.09.033","article-title":"Terbutaline in myasthenia gravis: A pilot study","volume":"277","author":"Soliven","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1093\/brain\/awz322","article-title":"Beta2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure","volume":"142","author":"Vanhaesebrouck","year":"2019","journal-title":"Brain"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","article-title":"Beneficial Effects of Corticosteroids on Ocular Myasthenia Gravis","volume":"53","author":"Kupersmith","year":"1996","journal-title":"Arch. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of Generalized Disease at 2 Years in Patients with Ocular Myasthenia Gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: Response to long-term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul","year":"2004","journal-title":"J. Neurol. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000116785","article-title":"Long-Term Results of Corticosteroid Therapy in Patients with Myasthenia Gravis","volume":"32","author":"Evoli","year":"1992","journal-title":"Eur. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: Report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/WNL.34.2.170","article-title":"Myasthenia gravis: Prolonged treatment with steroids","volume":"34","author":"Sghirlanzoni","year":"1984","journal-title":"Neurology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","article-title":"Clinical predictors of steroid-induced exacerbation in myasthenia gravis","volume":"13","author":"Bae","year":"2006","journal-title":"J. Clin. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jns.2018.10.018","article-title":"Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis","volume":"396","author":"Kanai","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM197401102900204","article-title":"Gradually Increasing Doses of Prednisone in Myasthenia Gravis. Reducing the hazards of treatment","volume":"290","author":"Seybold","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"ref_55","first-page":"1","article-title":"Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis","volume":"10","author":"Homedes","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of Myasthenia Gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol. Clin."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1749-6632.1993.tb35896.x","article-title":"The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine","volume":"685","author":"Elion","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00063030-199809010-00004","article-title":"Azathioprine: Clinical pharmacology and current indications in autoimmune disorders","volume":"9","author":"Anstey","year":"1998","journal-title":"BioDrugs"},{"key":"ref_59","first-page":"69","article-title":"Azathioprine and the neurologist","volume":"20","author":"McWilliam","year":"2019","journal-title":"Pract. Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/pgmj.66.772.102","article-title":"Long term treatment of myasthenia gravis with azathioprine","volume":"66","author":"Fonseca","year":"1990","journal-title":"Postgrad. Med. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ana.410150615","article-title":"Azathioprine in the treatment of myasthenia gravis","volume":"15","author":"Witte","year":"1984","journal-title":"Ann. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(97)05370-7","article-title":"Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis","volume":"150","author":"Bromberg","year":"1997","journal-title":"J. Neurol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Myasthenia Gravis Clinical Study Group (1993). A randomized clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J. Neurol. Neurosurg. Psychiatry, 56, 1157\u20131163.","DOI":"10.1136\/jnnp.56.11.1157"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00314245","article-title":"Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis","volume":"235","author":"Mantegazza","year":"1988","journal-title":"J. Neurol."},{"key":"ref_65","first-page":"106","article-title":"Outcome of Myasthenia gravis treated with high-dose prednisolone and azathioprine: A single centre ambispective study from India","volume":"26","author":"Dube","year":"2017","journal-title":"Acta Neurol. Taiwanica"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1749-6632.1981.tb33767.x","article-title":"Effect of immunosuppressive drugs (azathioprine)","volume":"377","author":"Mertens","year":"1981","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0960-8966(91)90005-D","article-title":"Azathioprine in myasthenia gravis: Observations in 41 patients and a review of literature","volume":"1","author":"Kuks","year":"1991","journal-title":"Neuromuscul. Disord."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamaneurol.2020.5407","article-title":"Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis: A Randomized Clinical Trial","volume":"78","author":"Sharshar","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/mus.25052","article-title":"Remission And relapse of myasthenia gravis on long-term azathioprine: An ambispective study","volume":"54","author":"Gupta","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1212\/WNL.36.1.35","article-title":"Azathioprine toxicity in neuromuscular disease","volume":"36","author":"Kissel","year":"1986","journal-title":"Neurology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/WNL.38.2.258","article-title":"Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis","volume":"38","author":"Hohlfeld","year":"1988","journal-title":"Neurology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/MPA.0000000000001914","article-title":"Frequency, Predisposing Factors, and Clinical Outcome of Azathioprine-Induced Pancreatitis Among Patients with Inflammatory Bowel Disease: Results from a Tertiary Referral Center","volume":"50","author":"Eskazan","year":"2021","journal-title":"Pancreas"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1093\/rheumatology\/kex389","article-title":"BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs","volume":"56","author":"Ledingham","year":"2017","journal-title":"Rheumatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ana.410170304","article-title":"Myasthenia gravis: Reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine","volume":"17","author":"Hohlfeld","year":"1985","journal-title":"Ann. Neurol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/jaut.1996.0111","article-title":"FK506 Prevents Induction of Rat Experimental Autoimmune Myasthenia Gravis","volume":"10","author":"Yoshikawa","year":"1997","journal-title":"J. Autoimmun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics","volume":"40","author":"Kino","year":"1987","journal-title":"J. Antibiot."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro","volume":"40","author":"Kino","year":"1987","journal-title":"J. Antibiot."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.transproceed.2004.01.018","article-title":"Pharmacology of calcineurin antagonists","volume":"36","author":"Kapturczak","year":"2004","journal-title":"Transplant. Proc."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"594152","DOI":"10.3389\/fneur.2020.594152","article-title":"Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients","volume":"11","author":"Fan","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","article-title":"Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis","volume":"11","author":"Zhao","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","article-title":"Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis","volume":"64","author":"Ponseti","year":"2005","journal-title":"Neurology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mus.10472","article-title":"Clinical study of fk506 in patients with myasthenia gravis","volume":"28","author":"Konishi","year":"2003","journal-title":"Muscle Nerve"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)","volume":"76","author":"Konishi","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jns.2017.05.060","article-title":"A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis","volume":"379","author":"Ahn","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of Low-Dose FK506 in the Treatment of Myasthenia gravis\u2014A Randomized Pilot Study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur. Neurol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2169\/internalmedicine.47.0513","article-title":"Long-term Treatment of Steroid-dependent Myasthenia Gravis Patients with Low-dose Tacrolimus","volume":"47","author":"Nagaishi","year":"2008","journal-title":"Intern. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s00415-017-8616-7","article-title":"Efficacy and safety of tacrolimus for myasthenia gravis: A systematic review and meta-analysis","volume":"264","author":"Wang","year":"2017","journal-title":"J. Neurol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ene.13189","article-title":"Adequate tacrolimus concentration for myasthenia gravis treatment","volume":"24","author":"Kanai","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jocn.2019.02.004","article-title":"Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis","volume":"63","author":"Wang","year":"2019","journal-title":"J. Clin. Neurosci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"912.2","DOI":"10.1212\/WNL.51.3.912-a","article-title":"Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil","volume":"51","author":"Hauser","year":"1998","journal-title":"Neurology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/1097-4598(200008)23:8<1287::AID-MUS22>3.0.CO;2-L","article-title":"Treatment of myasthenia gravis with mycophenolate mofetil: A case report","volume":"23","author":"Meriggioli","year":"2000","journal-title":"Muscle Nerve"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000050759","article-title":"Mycophenolate Mofetil: A New Immunosuppressive Approach Successful Treatment in a Case of Myasthenia gravis Associated with Incomplete Lupus erythematosus Syndrome and Hepatitis C Virus Infection","volume":"46","author":"Caponnetto","year":"2001","journal-title":"Eur. Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: An open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-510X(01)00478-6","article-title":"Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis","volume":"185","author":"Mowzoon","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000050768","article-title":"Mycophenolate mofetil in the therapy of severe myasthenia gravis","volume":"46","author":"Schneider","year":"2001","journal-title":"Eur. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: An analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00415-008-0718-9","article-title":"Mycophenolate mofetil for ocular myasthenia","volume":"255","author":"Chan","year":"2008","journal-title":"J. Neurol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Muscle Study Group (2008). A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology, 71, 394\u2013399.","DOI":"10.1212\/01.wnl.0000312373.67493.7f"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1196\/annals.1405.031","article-title":"Lessons from Two Trials of Mycophenolate Mofetil in Myasthenia Gravis","volume":"1132","author":"Sanders","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/mus.24608","article-title":"Two steps forward, one step back: Mycophenolate mofetil treatment for myasthenia gravis in the united states","volume":"51","author":"Burns","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mus.24694","article-title":"Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis","volume":"52","author":"Hehir","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","article-title":"Clinical Pharmacokinetics of Mycophenolate Mofetil","volume":"34","author":"Bullingham","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1681\/ASN.V1061366","article-title":"Newer immunosuppressive drugs: A review","volume":"10","author":"Gummert","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A Clinical Therapeutic Trial of Cyclosporine in Myasthenia Gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary Results of a Double-Blind, Randomized, Placebo-Controlled Trial of Cyclosporine in Myasthenia Gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s004150050141","article-title":"Long-term cyclosporine treatment in a group of severe myasthenia gravis patients","volume":"244","author":"Bonifati","year":"1997","journal-title":"J. Neurol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.55.3.448","article-title":"Retrospective analysis of the use of cyclosporine in myasthenia gravis","volume":"55","author":"Ciafaloni","year":"2000","journal-title":"Neurology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","article-title":"Cyclosporine in the treatment of myasthenia gravis","volume":"111","author":"Lavrnic","year":"2005","journal-title":"Acta Neurol. Scand."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s004150050360","article-title":"Cyclosporine neurotoxicity: A review","volume":"246","author":"Gijtenbeek","year":"1999","journal-title":"J. Neurol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s10384-009-0747-7","article-title":"A case of cyclosporine-induced optic neuropathy with a normal therapeutic level of cyclosporine","volume":"54","author":"Akagi","year":"2010","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/CND.0000000000000342","article-title":"Methotrexate as a Steroid-Sparing Agent in Myasthenia Gravis: A Preliminary Retrospective Study","volume":"23","author":"Rodolico","year":"2021","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_121","first-page":"S95","article-title":"Side effects and management of side effects of methotrexate in rheumatoid arthritis","volume":"28","author":"Albrecht","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"Huitema","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1212\/WNL.31.1.32","article-title":"Stable remissions in myasthenia grams","volume":"31","author":"Perez","year":"1981","journal-title":"Neurology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/archneur.1986.00520020049018","article-title":"Immunosuppressive Drug Therapy in Myasthenia Gravis","volume":"43","author":"Niakan","year":"1986","journal-title":"Arch. Neurol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/jnnp.2003.019232","article-title":"High dose cyclophosphamide for severe refractory myasthenia gravis","volume":"75","author":"Gladstone","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_126","first-page":"31","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"Schottlender","year":"2002","journal-title":"Muscle Nerve Off. J. Am. Assoc. Electrodiagn. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u201cRebooting\u201d with high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann. Neurol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jocn.2014.03.019","article-title":"Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis","volume":"21","author":"Nagappa","year":"2014","journal-title":"J. Clin. Neurosci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archneurol.2009.28","article-title":"Allogeneic Hematopoietic Cell Transplantation for Refractory Myasthenia Gravis","volume":"66","author":"Strober","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/pr.2011.57","article-title":"Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases","volume":"71","author":"Daikeler","year":"2012","journal-title":"Pediatr. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"Anti-Cancer Drugs"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: A pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J. Pediatr."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","article-title":"Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma","volume":"77","author":"Gajra","year":"2004","journal-title":"Am. J. Hematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody\u2013positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s00277-005-1050-4","article-title":"Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma","volume":"84","author":"Takagi","year":"2005","journal-title":"Ann. Hematol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jnnp.2006.093567","article-title":"Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis","volume":"78","author":"Baek","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/jnnp-2018-319410","article-title":"Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab","volume":"90","author":"Chan","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1007\/s00415-019-09296-y","article-title":"Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study","volume":"266","author":"Singh","year":"2019","journal-title":"J. Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: Extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: A comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J. Neurol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mus.26876","article-title":"Rituximab in late-onset myasthenia gravis is safe and effective","volume":"62","author":"Sahai","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_145","first-page":"e376","article-title":"Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study","volume":"98","author":"Nowak","year":"2021","journal-title":"Neurology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/ene.14391","article-title":"Efficacy and safety of rituximab in myasthenia gravis: A French multicentre real-life study","volume":"27","author":"Noury","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jneuroim.2016.07.009","article-title":"Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis","volume":"298","author":"Lebrun","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"736190","DOI":"10.3389\/fneur.2021.736190","article-title":"Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: A retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1478-3231.2010.02396.x","article-title":"The difficulties of managing severe hepatitis B virus reactivation","volume":"31","author":"Roche","year":"2011","journal-title":"Liver Int."},{"key":"ref_152","first-page":"480","article-title":"Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: A systematic review","volume":"31","author":"Cholongitas","year":"2018","journal-title":"Ann. Gastroenterol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"696385","DOI":"10.3389\/fneur.2021.696385","article-title":"Eculizumab Pharmacokinetics and Pharmacodynamics in Patients with Generalized Myasthenia Gravis","volume":"12","author":"Monteleone","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","article-title":"Post-intervention Status in Patients with Refractory Myasthenia Gravis Treated with Eculizumab During REGAIN and Its Open-Label Extension","volume":"96","author":"Mantegazza","year":"2021","journal-title":"Neurology"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.27326","article-title":"The use of eculizumab in ventilator-dependent myasthenia gravis patients","volume":"64","author":"Usman","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/acn3.51376","article-title":"Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: Responder analyses","volume":"8","author":"Jr","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The Neonatal Fc Receptor (FcRn): A Misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/archinte.1986.00360190143020","article-title":"High-dose intravenous immunoglobulin in the management of myasthenia gravis","volume":"146","author":"Arsura","year":"1986","journal-title":"Arch. Intern. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann. Neurol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<551::AID-MUS14>3.0.CO;2-O","article-title":"Immunoglobulin treatment in refractory myasthenia gravis","volume":"23","author":"Achiron","year":"2000","journal-title":"Muscle Nerve Off. J. Am. Assoc. Electrodiagn. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1007\/s00415-021-10544-3","article-title":"Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis","volume":"268","author":"Lotan","year":"2021","journal-title":"J. Neurol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2013.10.043","article-title":"Maintenance IVIg therapy in myasthenia gravis does not affect disease activity","volume":"338","author":"Hellmann","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/jnnp.57.Suppl.55","article-title":"Experience with intravenous immunoglobulin in myasthenia gravis: A review","volume":"57","author":"Edan","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF02335664","article-title":"High-dose intravenous immunoglobulin in myasthenia gravis","volume":"14","author":"Evoli","year":"1993","journal-title":"Ital. J. Neurol. Sci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0404.1991.tb04912.x","article-title":"Treatment of myasthenia gravis with high-dose intravenous immunoglobulin","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurol. Scand."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00002826-200105000-00010","article-title":"The Use of Intravenous Immunoglobulin as Maintenance Therapy in Myasthenia Gravis","volume":"24","author":"Hilkevich","year":"2001","journal-title":"Clin. Neuropharmacol."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Gajdos, P., Chevret, S., and Toyka, K.V. (2012). Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD002277.pub4"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","article-title":"Complications of intravenous immune globulin treatment in neurologic disease","volume":"47","author":"Brannagan","year":"1996","journal-title":"Neurology"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/jnnp.56.7.830-a","article-title":"Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis","volume":"56","author":"Meiner","year":"1993","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000081465","article-title":"Thromboembolic Complications of Intravenous Immunoglobulin Treatment","volume":"52","author":"Vucic","year":"2004","journal-title":"Eur. Neurol."},{"key":"ref_179","first-page":"157","article-title":"Intravenous immunoglobulin induced-nephropathy: A complication of IVIG therapy","volume":"11","author":"Ahsan","year":"1998","journal-title":"J. Nephrol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1159\/000169055","article-title":"Acute Renal Failure following Immunoglobulin Therapy","volume":"16","author":"Ahsan","year":"1996","journal-title":"Am. J. Nephrol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1526-0968.2000.004004280.x","article-title":"Plasma Exchange for Treatment of Myasthenia Gravis: Pathophysiologic Basis and Clinical Experience","volume":"4","author":"Qureshi","year":"2000","journal-title":"Ther. Apher."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1468-1331.2009.02729.x","article-title":"Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis","volume":"16","author":"Yeh","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","article-title":"Immunoglobulin Treatment Versus Plasma Exchange in Patients with Chronic Moderate to Severe Myasthenia Gravis","volume":"25","author":"Ravnborg","year":"2001","journal-title":"Artif. Organs"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jns.2007.05.033","article-title":"MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis","volume":"263","author":"Yeh","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1002\/acn3.50901","article-title":"Clinical outcome measures following plasma exchange for MG exacerbation","volume":"6","author":"Raja","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jca.21694","article-title":"Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status","volume":"34","author":"Usmani","year":"2019","journal-title":"J. Clin. Apher."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaneurol.2014.17","article-title":"Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis","volume":"71","author":"Liew","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1744-9987.2009.00684.x","article-title":"Periodic Therapeutic Plasma Exchange in Patients with Moderate to Severe Chronic Myasthenia Gravis Non-Responsive to Immunosuppressive Agents: An Eight Year Follow-Up","volume":"13","author":"Triantafyllou","year":"2009","journal-title":"Ther. Apher. Dial."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mus.23626","article-title":"Safety of plasma exchange therapy in patients with myasthenia gravis","volume":"47","author":"Ebadi","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/trf.14479","article-title":"Vascular access for therapeutic plasma exchange","volume":"58","author":"Ipe","year":"2018","journal-title":"Transfusion"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jca.21409","article-title":"Bilateral pneumothorax: A rare complication of central venous catheter placement for plasmapheresis years after thymectomy","volume":"31","author":"Gera","year":"2016","journal-title":"J. Clin. Apher."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/ALN.0b013e3182835192","article-title":"Perioperative Therapeutic Plasmapheresis","volume":"118","author":"Youngblood","year":"2013","journal-title":"Anesthesiology"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jama.1941.02820440037009","article-title":"The treatment of myasthenia gravis by removal of the thymus gland\u2014Preliminary report","volume":"117","author":"Blalock","year":"1941","journal-title":"J. Am. Med. Assoc."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.21037\/jtd-2019-rts-10","article-title":"Robotic thymectomy for myasthenia gravis surgical techniques and outcomes","volume":"13","author":"Raza","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.athoracsur.2021.06.071","article-title":"Perioperative Outcomes of Thymectomy in Myasthenia Gravis: A Thoracic Surgery Database Analysis","volume":"113","author":"Raja","year":"2021","journal-title":"Ann. Thorac. Surg."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/00207454.2016.1257993","article-title":"Prognosis of thymectomy in myasthenia gravis patients with thymus hyperplasia","volume":"127","author":"Yang","year":"2017","journal-title":"Int. J. Neurosci."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mus.26404","article-title":"Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis","volume":"59","author":"Ba","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1749-6632.1976.tb47718.x","article-title":"Alternate-day prednisone: Preliminary report of a double-blind controlled study","volume":"274","author":"Howard","year":"1976","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"117274","DOI":"10.1016\/j.jns.2020.117274","article-title":"Ocular myasthenia gravis\u2014How effective is low dose prednisone long term?","volume":"420","author":"Verma","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1196\/annals.1254.064","article-title":"Mycophenolate mofetil for myasthenia gravis: A double-blind, placebo-controlled pilot study","volume":"998","author":"Meriggioli","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/10428194.2011.615426","article-title":"Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: Case reports and review of literature","volume":"53","author":"Rezania","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/acn3.51121","article-title":"Consistent improvement with eculizumab across muscle groups in myasthenia gravis","volume":"7","author":"Mantegazza","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","article-title":"High-Dose Intravenous Methylprednisolone in Myasthenia Gravis","volume":"42","author":"Arsura","year":"1985","journal-title":"Arch. Neurol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00000441-198805000-00005","article-title":"Effects of Repeated Doses of Intravenous Immunoglobulin in Myasthenia Gravis","volume":"295","author":"Arsura","year":"1988","journal-title":"Am. J. Med. Sci."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/jnnp-2011-301449","article-title":"Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis","volume":"84","author":"Barnett","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mus.10224","article-title":"Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis","volume":"26","author":"Wolfe","year":"2002","journal-title":"Muscle Nerve"},{"key":"ref_211","unstructured":"Gronseth, G.S., Cox, J., Gloss, D., Merillat, S., Dittman, J., Armstrong, M.J., and Getchius, T.S.D. (2022, March 09). 2017 AAN Clinical Practice Guideline Process Manual. Available online: https:\/\/www.aan.com\/siteassets\/home-page\/policy-and-guidelines\/guidelines\/about-guidelines\/17guidelineprocman_pg.pdf."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1212\/01.wnl.0000342200.58823.6a","article-title":"Levels of evidence: Taking Neurology to the next level","volume":"72","author":"Gross","year":"2009","journal-title":"Neurology"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","article-title":"The natural course of myasthenia gravis: A long term follow up study","volume":"52","author":"Oosterhuis","year":"1989","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1756285617749134","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: Clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_216","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J. Biol. Med."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/mus.24536","article-title":"Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis","volume":"52","author":"Buzzard","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/jnnp.68.2.214","article-title":"Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis","volume":"68","author":"Komiyama","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11940-011-0151-8","article-title":"Treatment of ocular myasthenia gravis","volume":"14","author":"Haines","year":"2012","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/01.wnl.0000183145.91579.74","article-title":"Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG","volume":"65","author":"Hatanaka","year":"2005","journal-title":"Neurology"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: A double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurol. Scand."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000062987","article-title":"The effect of combined therapy with immunoadsorption and high-dose intravenous methylprednisolone on myasthenia gravis","volume":"48","author":"Munakata","year":"2002","journal-title":"Eur. Neurol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2019.05.003","article-title":"Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis","volume":"402","author":"Ozawa","year":"2019","journal-title":"J. Neurol. Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/6\/1597\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:36:02Z","timestamp":1760135762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/6\/1597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":224,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jcm11061597"],"URL":"https:\/\/doi.org\/10.3390\/jcm11061597","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]}}}